Esperion Therapeutics Initiates Phase I Clinical Study fo... ( PLYMOUTH Mich. Nov. 13 /- Esperion Th...)

Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002

Date:11/13/2009

PLYMOUTH, Mich., Nov. 13 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins. The single escalating dose study in healthy volunteers will be the first clinical study conducted by Esperion since the re-establishment of the company in May 2008.

ETC-1002 is being developed to treat dyslipidemia, an early-stage risk factor of coronary artery disease and associated metabolic syndromes. The compound targets lipid metabolism in two ways: first, by inhibiting fatty acid and cholesterol synthesis; and second, by enhancing oxidation of fatty acids. ETC-1002 therefore has the potential to lower LDL-C and triglycerides and also to increase HDL-C.

"Our pre-clinical research related to ETC-1002 has been very promising, and we are pleased to advance this new product candidate to clinical development. ETC-1002 is the flagship product of our dyslipidemia program, and it will also be the first product in our pipeline to reach clinical-stage development," said Roger Newton, PhD, FAHA, president and CEO of Esperion Therapeutics. "Just over a year and a half following the re-establishment of Esperion, we continue to progress toward our goal of bringing breakthrough cardiovascular and metabolic disease therapies to market."

Cardio-metabolic diseases are the leading cause of morbidity and mortality among men and women in industrialized countries around the world.

"We are very well positioned to move ahead with the development effort for ETC-1002 as we also advance our other promising pre-clinical research programs in both acute and chronic therapies to treat cardiovascular and metabolic disorders," Mr.
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
3. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
4. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
5. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
6. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
7. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch

Post Your Comments:

(Date:5/21/2013)... 2013 SoundConnect is pleased to announce ... for customers in Canada. Lync is the next ... allow businesses and organizations to collaborate and communicate much ... Lync in the United States. With the progressive rollout ... release in Canada, SoundConnect now offers a complete Microsoft ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 The Formulate ... display solution for sales and marketing teams looking for a ... describes the kit as “everything you’ll need to put together ... Display Kit comes with a number of displays and accessories ... booth 20 feet by 20 feet in size. These components ...

(Date:5/20/2013)... , May 20, 2013 ... Agricultural Research Service (ARS) in treatment of mastitis ... , Trials to begin in the second ... delivery technology company Phosphagenics Limited (ASX: POH, ... Agriculture,s (USDA) Agricultural Research Service (ARS) to develop and ...

(Date:5/20/2013)... Mechanicsburg, Pa (PRWEB) May 20, 2013 ... controller with ramp/soak capabilities. The 5R6-900 benchtop controller ... enclosure, the device can be plugged into the wall ... own power supply. This distinctive detail makes the device ... , The laboratory temperature controller can also be ...

Breaking Biology Technology:SoundConnect Announces Microsoft Lync Release in Canada 2 SoundConnect Announces Microsoft Lync Release in Canada 3 GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2 Phosphagenics Signs Research Agreement with the Agricultural Research Service 2 New Laboratory Temperature Controller by Oven Industries 2

[0] SoundConnect Announces Microsoft Lync Release in Canada [0] GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit [0] Phosphagenics Signs Research Agreement with the Agricultural Research Service [0] New Laboratory Temperature Controller by Oven Industries

... COLUMBIA, Md., Dec. 16 Martek Biosciences Corporation (Nasdaq: MATK ... fiscal year ended October 31, 2009. Revenues for the fourth quarter ... quarter of fiscal 2008. Net income was $11.0 million, or $0.33 ... 5% increase compared with $10.5 million, or $0.31 per diluted share, ...

... Organisms ... ... at the U.S. Department of Energy’s (DOE) Argonne National Laboratory and Northwestern University, Evanston, ... providing insights for design of bio-inspired dynamically adaptive materials for energy. , , ,“The ...

... , , , , WALTHAM, Mass., Dec. 16 ... advisory firms for pharmaceutical and healthcare issues, finds that, ... Stelara and Abbott,s briakinumab (both interleukin inhibitors) will capture ... the drug market for moderate to severe psoriasis. Among ...

Martek Announces Fourth Quarter and FY 2009 Financial Results Argonne Scientists Use Bacteria to Power Simple Machines In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market

(Date:5/18/2013)... The AGA Research Foundation is honored to announce the ... Digestive Cancer, which will support Andrew D. Rhim, MD, ... of Pennsylvania, Philadelphia, as he furthers his research on ... cancer progression. , "The AGA Research Foundation is humbled ... clinicians and AGA Legacy Society members," said Nicholas F. ...

(Date:5/18/2013)... 18, 2013) Research presented at Digestive Disease ... health through diet and lifestyle. , Individuals ... reduced muscle strength, fatigue and poor quality of ... are in remission. A randomized, double blind, placebo-controlled ... D supplementation corresponded to significant relief of these ...

(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...

Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2 Research examines new methods for managing digestive health 2 Research examines new methods for managing digestive health 3 New gut microbiome research to explore red meat -- colorectal cancer pathway 2

[0] AGA Research Foundation grant furthers digestive cancer research [0] Research examines new methods for managing digestive health [0] New gut microbiome research to explore red meat -- colorectal cancer pathway

... , This release is available in German . ... genes in the cells of their victim in order to ,reprogram, ... to live, making lots of new viruses instead. Luckily, ... is ensured by the cells, own sensors that recognise alien genetic ...

... Biometrics, Inc. (OTC Bulletin Board: PBME) ("PBI" or "the Company"), ... services, today announced its operating results for the first quarter ... call to discuss its FY2010 first quarter operating results at ... the three months ended September 30, 2009, revenues increased 27% ...

... In the largest, most comprehensive genetic analysis of ... has identified five new gene regions, including one involved ... inflammation of the digestive tract that characterizes the disease. ... Hakon Hakonarson, M.D., Ph.D., director of the Center for ...

Study shows link between influenza virus and fever Pacific Biometrics Inc. Reports First Quarter Operating Results Largest gene study of childhood IBD identifies 5 new genes

Concentration: 1mg/ml. Antigen: Propidium Iodide ...

Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...

Barcoded Slides, 5 Packs of 5 Slides (25/Case)...

Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...

Biology Products:

Propidium Iodide from GeneTex Mouse Anti-Mouse Qa.m7 Monoclonal Antibody, Unconjugated, Clone 5035-50.1 from CEDARLANE Laboratories Limited Corning GAPS II Slides from Invitrogen Mouse Anti-Mouse Qa.m8 Monoclonal Antibody, Unconjugated, Clone 5035-24.1 from CEDARLANE Laboratories Limited